thymosin alpha-1
PeptideexperimentalCOVID-19
Clinical trial activity
15 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
2
Phase 4
3
Earliest trial started Jun 4, 2009 (NCT05898451)
Timeline
Indications
Approved for
Mechanism of action
- Prothymosin alphaSupplementation
PTMA supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CO)NC(=O)[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CS)C(C)C)C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)O)C(C)C)C(C)C)C(C)C)[C@H](C)O- Mol. weight
- 3051.38 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL412531 ↗
Also known as
- peg-talpha1
- peg-tα1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06966687 | N/A | Apr 1, 2025 | Capital Medical University, Guangzhou Medical University, Huazhong University of Science and Technology, Nanjing Medical University, Sichuan University |
| NCT06598839 | N/A | Jun 30, 2024 | Chinese Academy of Medical Sciences |
| NCT06178146 | Phase 4 | Sep 1, 2023 | Shandong first medical University, Shandong Province Qianfoshan Hospital |
| NCT06139419 | Phase 2 | Jul 25, 2023 | Sun Yat-Sen University |
| NCT05487469 | N/A | Jul 1, 2022 | Nanjing Medical University |
| NCT05086614 | Phase 3 | Apr 1, 2021 | Fudan University |
| NCT04524169 | Phase 4 | Nov 1, 2020 | Jiao Tong University |
| NCT04268537 | Phase 2 | Feb 10, 2020 | Southeast University |
| NCT03663764 | Phase 2 | Aug 13, 2018 | Sun Yat-Sen University |
| NCT03448744 | Phase 4 | Oct 25, 2017 | Fudan University |
| NCT03082885 | N/A | Mar 18, 2017 | Sun Yat-Sen University |
| NCT03509688 | N/A | Nov 30, 2014 | Chinese Academy of Medical Sciences, Jilin University |
| NCT02366247 | Phase 3 | Aug 1, 2013 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Nanjing Medical University |
| NCT02366208 | Phase 2 | May 1, 2011 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Nanjing Medical University |
| NCT05898451 | Phase 2 | Jun 4, 2009 | Refnot-Pharm Ltd |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Medical University | Academic/Hospital | 4 | 2 | 3 | 2011 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 3 | 2 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 1 | 1 | 2014 |
| Fudan University | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 2 | 2011 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Jilin University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Refnot-Pharm Ltd | For profit | 1 | 1 | 1 | 2009 |
| Shandong first medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Southeast University | Academic/Hospital | 1 | 1 | 1 | 2020 |
15 organizations
Page 1 / 1